Heron Therapeutics (NASDAQ:HRTX – Get Free Report) and MPX International (OTCMKTS:MPXOF – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.
Profitability
This table compares Heron Therapeutics and MPX International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Heron Therapeutics | -22.52% | -293.02% | -10.00% |
| MPX International | N/A | N/A | N/A |
Analyst Ratings
This is a summary of current ratings and price targets for Heron Therapeutics and MPX International, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heron Therapeutics | 1 | 3 | 1 | 0 | 2.00 |
| MPX International | 0 | 0 | 0 | 0 | 0.00 |
Valuation & Earnings
This table compares Heron Therapeutics and MPX International”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Heron Therapeutics | $151.18 million | 0.42 | -$20.19 million | ($0.19) | -1.77 |
| MPX International | N/A | N/A | N/A | N/A | N/A |
MPX International has lower revenue, but higher earnings than Heron Therapeutics.
Institutional and Insider Ownership
80.0% of Heron Therapeutics shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Heron Therapeutics beats MPX International on 6 of the 9 factors compared between the two stocks.
About Heron Therapeutics
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
About MPX International
MPX International Corporation, operates as a cannabis company in Canada and internationally. It offers cannabis products under HOLYWEED, beleaf, SALSUS, MPX labs, Canveda, SPARTAN WELLNESS, HIGH12, STRAIN REE, PENNIES, Kingsway, DAIZE, and alice brands. The company was founded in 2015 and is headquartered in Toronto, Canada.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
